{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:02:52Z","timestamp":1792616572860,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41417-026-01034-7","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:03:17Z","timestamp":1777388597000},"page":"699-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-7005","authenticated-orcid":false,"given":"Catarina","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Bischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3471-9624","authenticated-orcid":false,"given":"Lea","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ahmadi-Erber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Bidet Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus K.","family":"Orlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-5163","authenticated-orcid":false,"given":"Henning","family":"Lauterbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6416-0586","authenticated-orcid":false,"given":"Josipa","family":"Raguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638360","volume":"11","author":"V Merz","year":"2021","unstructured":"Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, et al. Targeting KRAS: the elephant in the room of epithelial cancers. Front Oncol. 2021;11:638360.","journal-title":"Front Oncol"},{"key":"1034_CR2","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1200\/EDBK_325885","volume":"41","author":"N Coleman","year":"2021","unstructured":"Coleman N, Rodon J. Taking aim at the undruggable. Am Soc Clin Oncol Educ Book. 2021;41:e145\u2013e152.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1034_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong K-K. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"1034_CR4","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","volume":"27","author":"N Levin","year":"2021","unstructured":"Levin N, Paria BC, Vale NR, Yossef R, Lowery FJ, Parkhurst MR, et al. Identification and validation of T-cell receptors targeting RAS hotspot mutations in human cancers for use in cell-based immunotherapy, TCRs recognizing RAS mutations. Clin Cancer Res. 2021;27:5084\u201395.","journal-title":"Clin Cancer Res"},{"key":"1034_CR5","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"T Eric","year":"2016","unstructured":"Eric T, Robbins PF, Lu YC, Prickett TD, Gartner JJ, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375:2255\u201362.","journal-title":"N Engl J Med"},{"key":"1034_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732166","volume":"11","author":"H Lauterbach","year":"2021","unstructured":"Lauterbach H, Schmidt S, Katchar K, Qing X, Iacobucci C, Hwang A, et al. Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform. Front Oncol. 2021;11:732166.","journal-title":"Front Oncol"},{"key":"1034_CR7","doi-asserted-by":"publisher","first-page":"e008286","DOI":"10.1136\/jitc-2023-008286","volume":"12","author":"J Raguz","year":"2024","unstructured":"Raguz J, Pinto C, P\u00f6lzlbauer T, Habbeddine M, Rosskopf S, Strau\u00df J, et al. Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment. J Immunother Cancer. 2024;12:e008286.","journal-title":"J Immunother Cancer"},{"key":"1034_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15327","volume":"8","author":"SM Kallert","year":"2017","unstructured":"Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, M\u00fcller P, et al. Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. Nat Commun. 2017;8:15327.","journal-title":"Nat Commun"},{"key":"1034_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1809960","volume":"9","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Bonilla WV, Reiter A, Stemeseder F, Kleissner T, Oeler D, et al. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer. OncoImmunology. 2020;9:1809960.","journal-title":"OncoImmunology"},{"key":"1034_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100209","volume":"2","author":"WV Bonilla","year":"2021","unstructured":"Bonilla WV, Kirchhammer N, Marx A-F, Kallert SM, Krzyzaniak MA, Lu M, et al. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. Cell Rep Med. 2021;2:100209.","journal-title":"Cell Rep Med"},{"key":"1034_CR11","doi-asserted-by":"crossref","unstructured":"Ho A, Pearson A, Fu S, Posner M, Adkins D, Nabell L, et al. Abstract 679 Tumour CD8+ T cell responses in patients with recurrent\/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a Phase 1 study. https:\/\/www.sitcancer.org\/2023\/abstracts\/abstract-titles-publications?SITC%202023%20Titles%20with%20URLs%5Bquery%5D=679 2023.","DOI":"10.1136\/jitc-2023-SITC2023.0679"},{"key":"1034_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2021.100084","volume":"1","author":"J Choi","year":"2021","unstructured":"Choi J, Goulding SP, Conn BP, McGann CD, Dietze JL, Kohler J, et al. Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. Cell Rep Methods. 2021;1:100084.","journal-title":"Cell Rep Methods"},{"key":"1034_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175790","volume":"134","author":"AS Bear","year":"2024","unstructured":"Bear AS, Nadler RB, O\u2019Hara MH, Stanton KL, Xu C, Saporito RJ, et al. Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Investig. 2024;134:e175790.","journal-title":"J Clin Investig"},{"key":"1034_CR14","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/2326-6066.CIR-19-0107","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang Q, Douglass J, Hwang MS, Hsiue EH-C, Mog BJ, Zhang M, et al. Direct detection and quantification of neoantigens. Cancer Immunol Res. 2019;7:1748\u201354.","journal-title":"Cancer Immunol Res"},{"key":"1034_CR15","doi-asserted-by":"publisher","first-page":"e007097","DOI":"10.1136\/jitc-2023-007097","volume":"11","author":"CM Ade","year":"2023","unstructured":"Ade CM, Sporn MJ, Das S, Yu Z, Hanada K, Qi YA, et al. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics. J Immunother Cancer. 2023;11:e007097.","journal-title":"J Immunother Cancer"},{"key":"1034_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","volume":"142","author":"M Kanda","year":"2012","unstructured":"Kanda M, Matthaei H, Wu J, Hong S, Yu J, Borges M, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730\u2013733.e9.","journal-title":"Gastroenterology"},{"key":"1034_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1034_CR18","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"1034_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2022","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou S-HI, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2022;388:44\u201354.","journal-title":"N Engl J Med"},{"key":"1034_CR20","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381.","journal-title":"N Engl J Med"},{"key":"1034_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","volume":"209","author":"Biernacka","year":"2016","unstructured":"Biernacka, Tsongalis A, Peterson PD, Abreu JD, de FB, Black CC, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209:195\u20138.","journal-title":"Cancer Genet"},{"key":"1034_CR22","doi-asserted-by":"publisher","first-page":"e002560","DOI":"10.1136\/bmjopen-2013-002560","volume":"3","author":"C Boch","year":"2013","unstructured":"Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Gr\u00fcning W, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013;3:e002560.","journal-title":"BMJ Open"},{"key":"1034_CR23","doi-asserted-by":"publisher","unstructured":"Pfitzer L, Lybaert L, Bogaert C, Fant B. Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model. Preprint at https:\/\/doi.org\/10.1101\/2022.06.03.494687 (2022).","DOI":"10.1101\/2022.06.03.494687"},{"key":"1034_CR24","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1080\/21645515.2021.1974288","volume":"17","author":"Inven\u00e7\u00e3o","year":"2021","unstructured":"Inven\u00e7\u00e3o, da M, Melo CV, da AR, Mac\u00eado S, de LS, et al. Development of synthetic antigen vaccines for COVID-19. Hum Vaccines Immunother. 2021;17:3855\u201370.","journal-title":"Hum Vaccines Immunother"},{"key":"1034_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24562-2","volume":"12","author":"AS Bear","year":"2021","unstructured":"Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat Commun. 2021;12:4365.","journal-title":"Nat Commun"},{"key":"1034_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, et al. Lymph-node-targeted mKRAS-specific amphiphile vaccine in pancreatic AND colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30:531\u2013542.","journal-title":"Nat Med"},{"key":"1034_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024;30:1013\u20131022.","journal-title":"Nat Med"},{"key":"1034_CR28","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1158\/1078-0432.CCR-23-1212","volume":"30","author":"GP Linette","year":"2024","unstructured":"Linette GP, Bear AS, Carreno BM. Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin Cancer Res. 2024;30:2017\u201324.","journal-title":"Clin Cancer Res"},{"key":"1034_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct Target Ther. 2023;8:450.","journal-title":"Signal Transduct Target Ther"},{"key":"1034_CR30","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1016\/j.cell.2021.08.020","volume":"184","author":"ML Burger","year":"2021","unstructured":"Burger ML, Cruz AM, Crossland GE, Gaglia G, Ritch CC, Blatt SE, et al. Antigen dominance hierarchies shape TCF1(+) progenitor CD8 T cell phenotypes in tumors. Cell. 2021;184:4996\u20135014.e26.","journal-title":"Cell"},{"key":"1034_CR31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1046\/j.1365-2567.2002.01442.x","volume":"106","author":"MD Street","year":"2002","unstructured":"Street MD, Doan T, Herd KA, Tindle RW. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology. 2002;106:526\u201336.","journal-title":"Immunology"},{"key":"1034_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1745-7580-5-3","volume":"5","author":"MF Kotturi","year":"2009","unstructured":"Kotturi MF, Assarsson E, Peters B, Grey H, Oseroff C, Pasquetto V, et al. Of mice and humans: how good are HLA transgenic mice as a model of human immune responses? Immunome Res. 2009;5:3.","journal-title":"Immunome Res"},{"key":"1034_CR33","doi-asserted-by":"publisher","first-page":"e178945.","DOI":"10.1172\/JCI178945","volume":"134","author":"YR Chung","year":"2024","unstructured":"Chung YR, Awakoaiye B, Dangi T, Irani N, Fourati S, Penaloza-MacMaster P. An attenuated lymphocytic choriomeningitis virus vector enhances tumor control in mice partly via IFN-I. J Clin Investig. 2024;134:e178945.","journal-title":"J Clin Investig"},{"key":"1034_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25057-w","volume":"12","author":"SS Ring","year":"2021","unstructured":"Ring SS, Cupovic J, Onder L, L\u00fctge M, Perez-Shibayama C, Gil-Cruz C, et al. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. Nat Commun. 2021;12:4734.","journal-title":"Nat Commun"},{"key":"1034_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nm.2104","volume":"16","author":"L Flatz","year":"2010","unstructured":"Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med. 2010;16:339\u201345.","journal-title":"Nat Med"},{"key":"1034_CR36","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/eji.202048599","volume":"51","author":"AA de Waard","year":"2021","unstructured":"de Waard AA, Verkerk T, Jongsma MLM, Hoefakker K, Sethumadhavan S, Gerke C, et al. PAKC: A novel panel of HLA class I antigen presentation machinery knockout cells from the same genetic origin. Eur J Immunol. 2021;51:734\u2013737.","journal-title":"Eur J Immunol"},{"key":"1034_CR37","doi-asserted-by":"publisher","first-page":"64892","DOI":"10.18632\/oncotarget.17615","volume":"8","author":"S Jutz","year":"2017","unstructured":"Jutz S, Hennig A, Paster W, Asrak \u00d6, Dijanovic D, Kellner F, et al. A cellular platform for the evaluation of immune checkpoint molecules. Oncotarget. 2017;8:64892\u2013906.","journal-title":"Oncotarget"},{"key":"1034_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08304-z","volume":"10","author":"G Cafri","year":"2019","unstructured":"Cafri G, Yossef R, Pasetto A, Deniger DC, Lu Y-C, Parkhurst M, et al. Memory T cells targeting oncogenic mutations detected in the peripheral blood of epithelial cancer patients. Nat Commun. 2019;10:449.","journal-title":"Nat Commun"},{"key":"1034_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4:204\u201314.","journal-title":"Cancer Immunol Res"},{"key":"1034_CR40","doi-asserted-by":"publisher","first-page":"e0178220","DOI":"10.1371\/journal.pone.0178220","volume":"12","author":"C Battin","year":"2017","unstructured":"Battin C, Hennig A, Mayrhofer P, Kunert R, Zlabinger GJ, Steinberger P, et al. A human monocytic NF-\u03baB fluorescent reporter cell line for detection of microbial contaminants in biological samples. PLoS ONE. 2017;12:e0178220.","journal-title":"PLoS ONE"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01034-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:08:29Z","timestamp":1785517709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01034-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01034-7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CP, RB, SAE, KBH, SS, KKO, HL and JR are or were employees of Hookipa Pharma and its subsidiary Hookipa Biotech. LK and PS received research funding from Hookipa Pharma.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}